Christian Leisner, CDR-Life CEO
RA, Jeito and Omega back a small Swiss biotech to enter an I/O field paved by Adaptimmune
A licensing deal worth up to $520 million has been fueling little-known Swiss biotech CDR-Life since May 2020, but the five-year-old startup is ready to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.